Brokerages forecast that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will post $52.49 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ANI Pharmaceuticals’ earnings, with the highest sales estimate coming in at $53.27 million and the lowest estimate coming in at $51.70 million. ANI Pharmaceuticals reported sales of $38.21 million in the same quarter last year, which would suggest a positive year over year growth rate of 37.4%. The company is scheduled to report its next earnings results on Thursday, March 1st.

According to Zacks, analysts expect that ANI Pharmaceuticals will report full-year sales of $52.49 million for the current financial year, with estimates ranging from $181.20 million to $182.83 million. For the next fiscal year, analysts forecast that the business will report sales of $215.57 million per share, with estimates ranging from $207.53 million to $223.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter in the prior year, the company earned $1.09 EPS. ANI Pharmaceuticals’s revenue was up 25.0% compared to the same quarter last year.

ANIP has been the subject of several research reports. TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective on shares of ANI Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Tuesday, November 7th. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $68.25.

Institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 44.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 664 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its holdings in shares of ANI Pharmaceuticals by 132.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after acquiring an additional 2,390 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth approximately $197,000. Stevens Capital Management LP acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $207,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $210,000. 54.96% of the stock is owned by institutional investors and hedge funds.

Shares of ANI Pharmaceuticals (ANIP) opened at $70.67 on Friday. ANI Pharmaceuticals has a one year low of $42.23 and a one year high of $74.70. The stock has a market cap of $828.65, a PE ratio of 21.23 and a beta of 2.90. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45.

WARNING: “Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $52.49 Million” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/02/analysts-expect-ani-pharmaceuticals-inc-anip-will-announce-quarterly-sales-of-52-49-million.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.